Q2 2001 operating profit of EUR 150 million virtually at Q1 level (EUR 159 million) despite sharply deteriorating economic climate.
Sales up 5% on Q2 2000.
Interim dividend EUR 0.58 (2000: EUR 0.51) per ordinary share.
Second quarter (in EUR million) | 2001 | 2000 | +/- |
|---|---|---|---|
| Net sales | 2 087 | 1 988 | +5 % |
| Operating profit plus depreciation and amortization (EBITDA) | 279 | 374 | -25 % |
| Operating profit before amortization of goodwill (EBITA) | 157 | 239 | -34 % |
| – Life Science Products | 55 | 49 | +12 % |
| – Performance Materials | 35 | 40 | -12 % |
| – Polymers & Industrial Chemicals | 37 | 127 | -71 % |
| – Other activities | 30 | 23 | +30 % |
| Operating profit (EBIT) | 150 | 239 | -37 % |
| Profit on ordinary activities after taxation | 106 | 170 | -38 % |
| Extraordinary profit after taxation | – | – | – |
| Net profit | 106 | 169 | -37 % |
| Per ordinary share in EUR*: | |||
| – Profit on ordinary activities after taxation | 1.04 | 1.70 | -39 % |
| – Same as above, before amortization of goodwill | 1.12 | 1.70 | -34 % |
| – Net profit | 1.05 | 1.70 | -38 % |
| Average number of ordinary shares (x million) | 96.1 | 96.0 |
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
First half (in EUR million) | 2001 | 2000 | +/- |
|---|---|---|---|
| Net sales | 4 212 | 3 958 | +6 % |
| Operating profit plus depreciation and amortization (EBITDA) | 568 | 685 | -17 % |
| Operating profit before amortization of goodwill (EBITA) | 323 | 438 | -26 % |
| – Life Science Products | 113 | 97 | +16 % |
| – Performance Materials | 71 | 75 | -5 % |
| – Polymers & Industrial Chemicals | 82 | 224 | -63 % |
| – Other activities | 57 | 42 | +36 % |
| Operating profit (EBIT) | 309 | 438 | -29 % |
| Profit on ordinary activities after taxation | 212 | 307 | -31 % |
| Extraordinary profit after taxation | 70 | – | – |
| Net profit | 283 | 307 | -8 % |
| Per ordinary share in EUR*: | |||
| – Profit on ordinary activities after taxation | 2.09 | 3.07 | -32 % |
| – Same as above, before amortization of goodwill | 2.24 | 3.07 | -27 % |
| – Net profit | 2.84 | 3.07 | -7 % |
| Average number of ordinary shares (x million) | 96.0 | 96.5 |
* After deduction of dividend on cumulative preference shares
General
In the second quarter of 2001 DSM recorded a profit on ordinary activities after taxation of EUR 106 million, the same as in Q1 2001. Net earnings per share amounted to EUR 1.05.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCommenting on the Q2 results, Peter Elverding, chairman of the DSM Managing Board of Directors, said: “Given the sharply deteriorating economic conditions, I am not dissatisfied with a quarterly profit that is at the same level as the first quarter profit. Admittedly, the profit is substantially lower than our record profit for the second quarter of 2000, but without the portfolio shift towards Life Science Products and Performance Materials that we initiated several years ago and without our ongoing effort to improve our cost position, our profits would have been much lower. To me, this is a strong sign that we are heading in the right direction with our Vision 2005: Focus & Value strategy, one of the aims of which is to make our profits less cyclical.”
“I expect the Q1-to-Q2 downward trend in our operating profit to persist in the third quarter.”
Net sales
in EUR million | Second quarter: | First half: | ||
|---|---|---|---|---|
2001 | 2000 | 2001 | 2000 | |
| Life Science Products | 565 | 472 | 1 120 | 951 |
| Performance Materials | 494 | 553 | 989 | 1 076 |
| Polymers & Industrial Chemicals | 928 | 926 | 1 885 | 1 854 |
| Other activities | 100 | 37 | 218 | 77 |
| Total | 2 087 | 1 988 | 4 212 | 3 958 |
Net sales in the second quarter of 2001 amounted to EUR 2.1 billion, an increase of 5% compared with the second quarter of 2000. Despite the rapidly deteriorating economic climate DSM managed to achieve 3% autonomous volume growth. Acquisitions and divestments on balance resulted in a sales increase of 1%, and currency translation also accounted for an effect of +1%. Selling prices were on average 3% lower than in Q2 2000, while there was a 3% increase in net sales due to a change in DSM’s consolidation principles with effect from the financial year 2001.
Operating profit
DSM’s Q2 operating profit (after amortization of goodwill to an amount of EUR 7 million) amounted to EUR 150 million, which is 37% lower than the record profit in Q2 2000. The decrease was due to lower margins (selling prices less variable costs), especially in the Polymers & Industrial Chemicals cluster, with the exception of melamine. The operating profit for Life Science Products and Performance Materials combined was higher than in Q2 2000, especially if the divestment of DSM Engineering Plastic Products with effect from 1 January 2001 is taken into account.
Review by cluster
Life Science Products
in EUR million | Second quarter: | First half: | ||
|---|---|---|---|---|
2001 | 2000 | 2001 | 2000 | |
| Net sales including intra-Group supplies | 589 | 490 | 1 165 | 992 |
| Operating profit plus depreciation and amortization | 92 | 80 | 186 | 157 |
| Operating profit | 55 | 49 | 113 | 97 |
The cluster’s Q2 sales were up 20% from Q2 2000 and its operating profit rose 12%. DSM Fine Chemicals saw its sales increase substantially, but its operating profit was slightly lower; both developments were the net effect of a positive contribution from DSM Catalytica Pharmaceuticals and lower sales volumes for some custom pharmaceutical intermediates which could not immediately be compensated for by the introduction of new products. DSM Bakery Ingredients posted lower profits than in Q2 2000 due to a margin squeeze resulting from price increases for the raw material molasses. DSM Anti-Infectives and DSM Food Specialties posted higher profits as sales volumes and margins were up.
Performance Materials
in EUR million | Second quarter: | First half: | ||
|---|---|---|---|---|
2001 | 2000 | 2001 | 2000 | |
| Net sales including intra-Group supplies | 513 | 561 | 1 024 | 1 094 |
| Operating profit plus depreciation and amortization | 60 | 65 | 118 | 124 |
| Operating profit | 35 | 40 | 71 | 75 |
The sales figure adjusted for the divestment of DSM Engineering Plastic Products with effect from 1 January 2001 was at virtually the same level as in the second quarter of 2000. Sales volumes were slightly lower due to the adverse economic climate worldwide, especially in the automotive and electrics & electronics sectors, while selling prices were on average slightly higher. The operating profit adjusted for the above-mentioned divestment increased somewhat. DSM High Performance Fibers and DSM Desotech in particular showed an excellent performance.
Polymers & Industrial Chemicals
in EUR million | Second quarter: | First half: | ||
|---|---|---|---|---|
2001 | 2000 | 2001 | 2000 | |
| Net sales including intra-Group supplies | 1 004 | 1 009 | 2 056 | 2 011 |
| Operating profit plus depreciation and amortization | 84 | 192 | 178 | 335 |
| Operating profit | 37 | 127 | 82 | 224 |
Lower selling prices – except for melamine and fertilizers – resulted in a fractional decrease in Q2 sales compared with the second quarter of 2000. The petrochemicals business posted an increase in sales volumes. However, because of a decrease in margins the operating profit for this business was much lower than in Q2 2000, although it remained at the Q1 2001 level. Sales of industrial chemicals were down on Q2 2000 as both prices and sales volumes were under pressure, in particular in the caprolactam and acrylonitrile businesses. These factors, aggravated by higher raw material costs, caused the operating result for fibre intermediates to dip into the red. DSM Agro’s operating profit decreased strongly due to a decrease in margins and sales volumes. The melamine business saw its operating profit improve.
Other activities
in EUR million | Second quarter: | First half: | ||
|---|---|---|---|---|
2001 | 2000 | 2001 | 2000 | |
| Net sales including intra-Group supplies | 103 | 38 | 223 | 78 |
| Operating profit plus depreciation and amortization | 43 | 37 | 86 | 69 |
| Operating profit | 30 | 23 | 57 | 42 |
Sales were up on Q2 2000, mainly because the ABS tolling activities, which previously belonged to the Polymers & Industrial Chemicals cluster, were grouped under Other activities with effect from 1 January 2001, while the Noordgastransport joint venture has become part of DSM Energy as a result of a change in consolidation principles. The operating profit also increased, mainly on account of a higher contribution from DSM Energy.
Net profit
The balance of financial income and expense amounted to an interest expense of EUR 26 million, which is EUR 11 million higher than in Q2 2000. The increase was due to the financing of the acquisition of Catalytica Pharmaceuticals.
At 19%, the effective tax rate in Q2 2001 was lower than in Q2 2000 (27%). The decrease was due to the fact that the profit included a larger proportion of tax-exempt income and income taxed at a relatively low rate.
The profit on ordinary activities after taxation amounted to EUR 106 million, the same as in Q1 2001.
Compared with Q2 2000, DSM’s net profit decreased by EUR 63 million and stood at EUR 106 million.
Cash flow, capital expenditure and financing
In Q2 2001 the cash flow (net profit plus depreciation and amortization) amounted to EUR 235 million, which is EUR 69 million less than in Q2 2000. At EUR 171 million, capital expenditure was slightly higher than in Q2 2000 (EUR 161 million). Capital expenditure in the first half of 2001 amounted to EUR 270 million (H1 2000: EUR 300 million).
Balance sheet
The financial data of Catalytica Pharmaceuticals, whose acquisition was completed at the end of 2000, have been consolidated from the financial year 2001 onwards. In the balance sheet as at year-end 2000, the takeover sum was accounted for under Financial fixed assets in its entirety. The consolidation of this company led to major changes in the balance sheet.
Outlook
The economic slowdown that was already making itself felt in the first quarter continued more strongly than expected into the second quarter. In Europe and Asia the slowdown worsened, and the situation in the USA certainly showed no improvement. On the other hand, the prices of raw materials linked to oil and natural gas started to decrease. On balance, market conditions deteriorated in end markets that are important to DSM, such as the automotive industry, the E&E industry, the packaging sector and the textile industry. It is difficult to predict when these markets will start to recover.
Over the next few months DSM expects the profits of the Polymers & Industrial Chemicals cluster to be lower than in the first half of 2001. This will be the net effect of lower profits in petrochemicals and an improvement in results for industrial chemicals.
The Performance Materials cluster, too, will be under somewhat greater pressure from market developments.
DSM expects the profit growth in Life Science Products to continue at an increased pace.
All things considered, DSM expects the Q1-to-Q2 downward trend in its operating profit to persist in the third quarter.
Interim dividend
It has been decided to pay out an interim dividend of EUR 0.58 per ordinary share for 2001 (2000: EUR 0.51); this represents a third of the total dividend of EUR 1.75 paid out for 2000. The interim dividend is no indication of the total dividend for 2001. The interim dividend for 2001 will be paid out in cash.
Consolidated statement of income
in EUR million | Second quarter: | First half: | ||
|---|---|---|---|---|
2001 | 2000 | 2001 | 2000 | |
| Net sales | 2 087 | 1 988 | 4 212 | 3 958 |
| Operating profit plus depreciation and amortization (EBITDA) | 279 | 374 | 568 | 685 |
| Operating profit before amortization of goodwill (EBITA) | 157 | 239 | 323 | 438 |
| Amortization of goodwill | -7 | – | -14 | – |
| Operating profit (EBIT) | 150 | 239 | 309 | 438 |
| Balance of financial income and expense | -26 | -15 | -54 | -34 |
| Profit on ordinary activities before taxation | 124 | 224 | 255 | 404 |
| Tax on profit on ordinary activities | -23 | -60 | -56 | -109 |
| Profit of non-consolidated companies | 5 | 6 | 13 | 12 |
| Profit on ordinary activities after taxation | 106 | 170 | 212 | 307 |
| Extraordinary profit after taxation | – | – | 70 | – |
| Group profit after taxation | 106 | 170 | 282 | 307 |
| Minority interests’ share in profit | 0 | -1 | 1 | 0 |
| Net profit | 106 | 169 | 283 | 307 |
| Net profit | 106 | 169 | 283 | 307 |
| Dividend on cumulative preference shares | -5 | -5 | -11 | -11 |
| Net profit available to holders of ordinary shares | 101 | 164 | 272 | 296 |
| Cash flow | 235 | 304 | 542 | 554 |
| Depreciation and amortization | 129 | 135 | 259 | 247 |
| Capital expenditure | 171 | 161 | 270 | 300 |
| Per ordinary share in EUR*: | ||||
| – Profit on ordinary activities after taxation | 1.04 | 1.70 | 2.09 | 3.07 |
| – Same as above, before amortization of goodwill | 1.12 | 1.70 | 2.24 | 3.07 |
| – Net profit | 1.05 | 1.70 | 2.84 | 3.07 |
| – Cash flow | 2.39 | 3.11 | 5.53 | 5.63 |
| Interim dividend | 0.58 | 0.51 | ||
| Average number of ordinary shares (x million) | 96.1 | 96.0 | 96.0 | 96.5 |
| Number of ordinary shares, end of period (x million) | 96.1 | 95.4 | 96.1 | 95.4 |
| Workforce | 22 288 | **21 758 | ||
| – of which in The Netherlands | 10 531 | **10 662 | ||
* After deduction of dividend on cumulative preference shares
** year-end 2000; the year-end 2000 overall workforce figure adjusted for changes in consolidation principles, the acquisition of Catalytica Pharmaceuticals and the deconsolidation of DEPP was 22,737.
Consolidated balance sheet
in EUR million | 30 June 2001 | 31 December 2000 | ||
|---|---|---|---|---|
| Fixed assets | ||||
| Intangible fixed assets | 656 | 75 | ||
| Tangible fixed assets | 3 591 | 3 130 | ||
| Financial fixed assets | 370 | 1 326 | ||
| 4 617 | 4 531 | |||
| Current assets | ||||
| Inventories | 1 380 | 1 224 | ||
| Receivables | 2 181 | 1 888 | ||
Cash | 161 | 204 | ||
| 3 722 | 3 316 | |||
| Total | 8 339 | 7 847 | ||
| Group equity | ||||
| Shareholders’ equity | 3 137 | 3 040 | ||
| Minority interests’ share | 64 | 30 | ||
| 3 201 | 3 070 | |||
| Equalization account | 31 | 27 | ||
| Provisions | 966 | 857 | ||
| Long-term liabilities | 1 601 | 1 482 | ||
| Current liabilities | ||||
| – interest-bearing | 828 | 870 | ||
| – non-interest-bearing | 1 712 | 1 541 | ||
| 2 540 | 2 411 | |||
| Total | 8 339 | 7 847 | ||
| Capital employed | 6 096 | 4 776 | ||
| Net debt | 2 268 | 2 148 | ||
| Group equity / total assets | 0.38 | 0.39 | ||
| Net debt / group equity | 0.71 | 0.70 | ||
Statement of cash flows
First half (in EUR million) | 2001 | 2000 | ||
|---|---|---|---|---|
| Cash at beginning of period | 204 | 159 | ||
| Operating activities: | ||||
| – Cash flow | 542 | 554 | ||
| – Change in working capital | -196 | -124 | ||
| – Other changes | -155 | 51 | ||
| Net cash provided by operating activities | 191 | 481 | ||
| Investment activities: | ||||
| – Capital expenditure and capital payments | -285 | -319 | ||
| – Divestments | 206 | 12 | ||
| – Other changes | 42 | -3 | ||
| Net cash used in investing activities | -37 | -310 | ||
| Dividend paid | -134 | -54 | ||
| Net cash used in financial activities | -63 | -99 | ||
| Cash at end of period | 161 | 177 | ||
Statement of changes in Shareholders’ equity
First half (in EUR million) | 2001 | 2000 |
|---|---|---|
| Shareholders’ equity at beginning of period | 3 040 | 2 620 |
| Changes: | ||
| – Net profit | 283 | 307 |
| – Dividend on ordinary shares | -178 | -94 |
| – Dividend on cumprefs | -22 | -18 |
| – Exchange differences | 10 | 21 |
| – Share buy-back | – | -119 |
| – Other | 4 | 1 |
| Shareholders’ equity at end of period | 3 137 | 2 718 |
The financial information set out in this quarterly report is unaudited.
